Pharmafile Logo
Pharmafocus logo
Advanced Search

Cancer

Showing 15 posts of 1067 posts found.

shutterstock_141299494

Top UK doctors warn Boris Johnson that no-deal Brexit would cause key cancer therapy supply shortages

August 2, 2019
Manufacturing and Production, Medical Communications Cancer, NHS, UK, brexit, pharma

Top doctors from some of the UK’s foremost nuclear medicine associations have written a letter to recently-anointed Prime Minister Boris …

News
novartis_outside_1

Novartis’ Kisqali reinforces overall survival benefit in postmenopausal HR+/HER2- breast cancer

August 1, 2019
Research and Development Cancer, Kisqali, Novartis, breast cancer, pharma

New Phase 3 evidence has emerged on the efficacy of Novartis’ Kisqali (ribociclib) in combination with AstraZeneca’s Faslodex (fulvestrant) in …

News
lilly_entrance_web

Lilly’s Verzenio combo shows additional breast cancer survival benefit in new Phase 3 data

July 31, 2019
Research and Development Cancer, Eli Lilly, Verzenio, breast cancer, pharma

Eli Lilly has revealed new Phase 3 data on its CDK4 & 6 inhibitor Verzenio (abemaciclib), demonstrating its efficacy in …

News
fda2outsideweb

Bayer and Orion’s Nubeqa secures FDA approval in non-metastatic castration-resistant prostate cancer

July 31, 2019
Research and Development, Sales and Marketing Bayer, Cancer, Nubeqa, orion, pharma, prostate cancer

The FDA has awarded approval under its Priority Review pathway to Nubeqa (darolutamide) for the treatment of non-metastatic castration-resistant prostate …

News

Bayer’s Vitravki poised to become first tumour-agnostic therapy in EU following CHMP recommendation

July 30, 2019
Manufacturing and Production, Sales and Marketing Bayer, CHMP, Cancer, EU, Vitrakvi, pharma

Bayer’s oral TRK inhibitor Vitrakvi (larotrectinib) could be set to become the European Union’s first drug approved in a tumour-agnostic …

News
merck-keytruda

MSD’s Keytruda combo hits primary endpoint at Phase 3 in triple-negative breast cancer

July 30, 2019
Manufacturing and Production, Research and Development Cancer, MSD, breast cancer, keytruda, pharma

MSD’s blockbuster anti-PD-L1 immunotherapy Keytruda (pembrolizumab) has impressed in newly released Phase 3 data; the company announced that, when combined …

News
images

Roche’s Tecentriq combo recommended in Europe for non-small cell lung cancer

July 29, 2019
Sales and Marketing Cancer, NSCLC, Roche, lung cancer, pharma, tecentriq

Riche’s blockbuster immunotherapy Tecentriq (atezolizumab) is closing in on securing yet another approval after it revealed that the drug was …

News

AstraZeneca’s Lynparza approved via Cancer Drugs Fund for BRCA+ gynaecological cancers

July 26, 2019
Medical Communications, Sales and Marketing AstraZeneca, Cancer, Cancer Drugs Fund, NHS, NICE, UK, lynparza, pharma

NICE has published final guidance which approves AstraZeneca’s Lynparza (olaparib) for use on the NHS as a maintenance therapy for …

News

NICE greenlights Novartis Kisqali combo in HR+/HER2- advanced breast cancer

July 17, 2019
Manufacturing and Production, Medical Communications, Research and Development Cancer, Kisqali, NICE, Novartis, UK, breast cancer, pharma

Novartis’ Kisqali (ribociclib) has secured recommendation from NICE in combination with fulvestrant, meaning the cyclin-dependent kinase 4 and 6 (CDK4/6) …

News
astrazeneca_plaque

AstraZeneca’s Imfinzi gets orphan drug designation from FDA

July 12, 2019
Medical Communications AstraZeneca, Cancer, Imfinzi, lung cancer, pharma

AstraZeneca’s cancer immunotherapy Imfinzi has been granted orphan drug status as a treatment for small cell lung cancer (SCLC). The …

News

Scottish NHS patients to access Pfizer’s Ibrance combo in HR+/HER- breast cancer following SMC recommendation

July 11, 2019
Sales and Marketing Cancer, Scotland, Scottish Medicines Consortium, breast cancer, ibrance, pharma

Female NHS patients in Scotland will soon be able to access Pfizer’s cyclin-dependent kinase (CDK) 4/6 inhibitor Ibrance (palbociclib) after …

News
image_credit_united_states_mission_geneva

WHO leaves breakthrough cancer therapies off updated Essential Medicines List

July 10, 2019
Research and Development Cancer, EML, WHO, essential medicines list, oncology, pharma, world health organization

The World Health Organization (WHO) has updated its list of essential medicines to include 28 more drugs. The WHO’s Essential …

News
imp_pologne2

Pierre Fabre’s triplet therapy makes strong showing in BRAF V600E-mutant metastatic colorectal cancer

July 8, 2019
Research and Development, Sales and Marketing Cancer, Pierre Fabre, colorectal cancer, pharma

Pierre Fabre chose the European Society for Medical Oncology (ESMO) 21st World Congress on Gastrointestinal Cancer in Barcelona, Spain, to …

News
8655563196_1c0f83c447_z

New urine test can diagnose and offer prognosis for prostate cancer

July 8, 2019
Sales and Marketing Cancer, oncology, pharma, prostate cancer, urine test

A new urine test can diagnose cases of aggressive prostate cancer more quickly than invasive biopsies. The test can also …

News

NICE recommends Pfizer’s Vizimpro, rejects AstraZeneca’s Tagrisso, in non-small cell lung cancer

July 5, 2019
Medical Communications, Sales and Marketing Cancer, NHS, NICE, Pfizer, UK, Vizimpro, lung cancer, pharma

NICE has announced its decision to recommend Pfizer’s Vizimpro (Dacomitinib) in the treatment of non-small-cell lung cancer (NSCLC) – a …

News
The Gateway to Local Adoption Series

Latest content

Just – Evotec given Gates Foundation grant to increase global biotherapeutics access

January 8, 2026

Johnson & Johnson submits robotic surgical system for De Novo classification

January 8, 2026

EA Pharma announces phase 3 trial for new schizophrenia treatment in Japan

January 7, 2026

Eleva appoints Erich Rajkovic as Chief Business Officer

January 7, 2026

MedPharm announces US FDA inspection of North Carolina manufacturing facility

January 6, 2026